Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice.
| Autor: | Bergeron HC; Department of Infectious Diseases, University of Georgia, Athens, GA 30605, USA., Crabtree J; Department of Infectious Diseases, University of Georgia, Athens, GA 30605, USA., Nagy T; Department of Pathology, University of Georgia, Athens, GA 30605, USA., Martin DE; TrippBio, Inc., Jacksonville, FL 32256, USA., Tripp RA; Department of Infectious Diseases, University of Georgia, Athens, GA 30605, USA.; TrippBio, Inc., Jacksonville, FL 32256, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Viruses [Viruses] 2024 Jul 06; Vol. 16 (7). Date of Electronic Publication: 2024 Jul 06. |
| DOI: | 10.3390/v16071087 |
| Abstrakt: | Human metapneumovirus (HMPV) is an important cause of acute respiratory tract infection and causes significant morbidity and mortality. There is no specific antiviral drug to treat HMPV or vaccine to prevent HMPV. This study determined if probenecid, a host-targeting antiviral drug, had prophylactic (pre-virus) or therapeutic (post-virus) efficacy to inhibit HMPV replication in LLC-MK2 cells in vitro and in the lungs of BALB/c mice. This study showed that ≥0.5 μM probenecid significantly inhibited HMPV replication in vitro, and 2-200 mg/kg probenecid prophylaxis or treatment reduced HMPV replication in BALB/c mice. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|